Can a patient on apixaban (Eliquis) safely take fish‑oil supplements, and what dose is appropriate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Fish Oil Use with Apixaban (Eliquis)

Fish oil supplements can be safely taken with apixaban (Eliquis) at doses up to 3 grams per day without requiring dose adjustments or special monitoring, as fish oil does not interact with apixaban's CYP3A4 or P-gp metabolism pathways and clinical evidence shows no increased bleeding risk.

Key Mechanistic Considerations

The FDA-approved Eliquis label specifically addresses drug interactions that require dose modifications: only combined P-gp and strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, ritonavor) necessitate apixaban dose reduction 1. Fish oil does not inhibit or induce either of these pathways 2.

Apixaban is metabolized primarily through:

  • CYP3A4 enzyme system
  • P-glycoprotein (P-gp) transporter

Fish oil (omega-3 fatty acids) operates through entirely different mechanisms—affecting platelet function and inflammatory pathways—without interfering with apixaban's pharmacokinetics 2.

Clinical Evidence on Bleeding Risk

The concern about additive bleeding risk is not supported by clinical data:

  • A retrospective study of 182 patients taking high-dose fish oil (mean 3 g/day) plus aspirin and clopidogrel showed only 1 major bleeding event over 33 months of follow-up, with no statistical difference compared to controls on dual antiplatelet therapy alone 3.

  • Multiple studies examining fish oil with anticoagulants (including warfarin studies at doses of 3-6 g/day) have consistently shown no clinically significant increase in bleeding complications 4, 5.

  • While one case report suggested a warfarin interaction 6, this involved warfarin's vitamin K-dependent mechanism, which is fundamentally different from apixaban's direct factor Xa inhibition.

Recommended Dosing

For cardiovascular benefit and safety:

  • Standard dose: Up to 3 grams per day of combined EPA + DHA is recognized as safe by the FDA (GRAS status) 7
  • Higher doses up to 5 grams per day have not raised safety concerns in adults per international guidelines 7
  • Supplemental EPA alone up to 1.8 g/day or DHA alone up to 1 g/day are also considered safe 7

The Norwegian guidelines specifically concluded that fish oil supplements can provide positive health effects without appreciable risk of adverse effects 7.

Important Caveats

Quality matters: Choose pharmaceutical-grade fish oil supplements that have undergone purification to remove environmental contaminants (mercury, PCBs, dioxins) 4. Look for USP verification or prescription-grade preparations.

No apixaban dose adjustment needed: Unlike with strong CYP3A4/P-gp inhibitors, the apixaban dose should remain unchanged when adding fish oil 1.

Monitor for any unusual bleeding: While the risk is not elevated, standard monitoring for signs of bleeding (bruising, blood in urine/stool, prolonged bleeding from cuts) remains appropriate for any patient on anticoagulation.

Clinical Bottom Line

There is no pharmacokinetic or pharmacodynamic interaction between fish oil and apixaban that would contraindicate their combined use. Patients can safely take fish oil supplements at standard cardiovascular doses (1-3 g/day) without dose modification of their apixaban regimen 7, 3, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.